With refer to earlier intimation dated May 14, 2024, regarding the Board Meeting of the Company scheduled on May 21, 2024, to consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2024, Eris Lifesciences has informed that the meeting scheduled for May 21, 2024, the Board of Directors will also consider a proposal for fund raising by issuance of Non-Convertible Securities, through permissible modes under applicable law and subject to such regulatory/ statutory approvals, as may be required. Further, as informed vide letter dated March 27, 2024, the trading window has been already closed from April 01, 2024, and will remain closed till 48 hours after the declaration of financial results of the Company pursuant to SEBI [Prohibition of Insider Trading] Regulations, 2015 and Policy on ‘Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company for the purpose of Board Meeting.
The above information is a part of company’s filings submitted to BSE.